

**Table S2. ROC analysis of each variate in the plasma of early stages HCC, related to Figure 7.**

<b>Variate</b>	<b>AUC (95% CI)</b>	<b>Optimal Cut Off</b>	<b>SE (%)</b>	<b>SP (%)</b>	<b>Youden's index</b>	<b>PPV (%)</b>	<b>NPV (%)</b>	<b>PLR</b>	<b>NLR</b>	<b>OR (95% CI)</b>
<b>Exos Circ-CDYL</b>	<b>0.88 (0.81,0.93)</b>	<b>1.94</b>	<b>78.95</b>	<b>86.96</b>	<b>0.6591</b>	<b>92.59</b>	<b>66.67</b>	<b>6.05</b>	<b>0.24</b>	<b>2.12 (1.55,2.91)</b>
<b>EPCAM+ %</b>	<b>0.80 (0.72,0.86)</b>	<b>1.11</b>	<b>73.68</b>	<b>80.43</b>	<b>0.5411</b>	<b>87.50</b>	<b>53.62</b>	<b>3.77</b>	<b>0.33</b>	<b>2.82 (1.75,4.53)</b>
<b>LTi-Exos</b>	<b>0.88 (0.81,0.93)</b>	<b>0.51</b>	<b>84.21</b>	<b>84.78</b>	<b>0.6899</b>	<b>91.95</b>	<b>72.22</b>	<b>5.53</b>	<b>0.19</b>	<b>382.00 (58.38,2499.40)</b>
<b>AFP</b>	<b>0.70 (0.62,0.77)</b>	<b>18.00</b>	<b>46.32</b>	<b>97.83</b>	<b>0.4415</b>	<b>97.22</b>	<b>42.86</b>	<b>21.31</b>	<b>0.55</b>	<b>1.04 (1.00,1.08)</b>
<b>LTi-Exos +AFP</b>	<b>0.90 (0.83,0.94)</b>	<b>0.59</b>	<b>83.16</b>	<b>91.30</b>	<b>0.7446</b>	<b>95.18</b>	<b>72.41</b>	<b>9.56</b>	<b>0.18</b>	<b>494.27 (74.48,3280.05)</b>